Valeant looking to grow further but Meda rules itself out
This article was originally published in Scrip
Executive Summary
"We have acquired several attractive assets in the past few years that have bolstered our presence [in dermatology] across our geographic markets and we will continue to look for other assets that will continue this growth," said Valeant Pharmaceuticals' CEO J. Michael Pearson as recently as two weeks ago.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.